Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Puttemans, Janik, Dekempeneer, Yana, Eersels, Jos L., Hanssens, Heleen, Debie, Pieterjan, Keyaerts, Marleen, Windhorst, Albert D., van der Aa, Frank, Lecocq, Quentin, Breckpot, Karine, Morgenstern, Alfred, Bruchertseifer, Frank, Lahoutte, Tony, Devoogdt, Nick, D’Huyvetter, Matthias
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226418/
https://ncbi.nlm.nih.gov/pubmed/32326199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados